Table 2.
Number of Adverse Events Due to Neutropeniaa in HIV-Infected Kenyan Women Antepartum until Postpartum Week 104 Who Received Triple Antiretroviral Prophylaxis for Prevention of Mother-to-Child Transmission of HIV, Kisumu, Kenya, 2003–2009.b
| Weeks’ Gestation
|
Delivery (n = 450) |
Weeks’ Postpartum
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32–34 weeks (n = 472) |
35–36 weeks (n = 423) |
37–38 weeks (n = 361) |
39–41 weeks (n = 267) |
2 weeks (n = 440) |
6 weeks (n = 411) |
14 weeks (n = 414) |
24 weeks (n = 393) |
36 weeks (n = 349) |
52 weeks (n = 345) |
72 weeks (n = 319) |
104 weeks (n = 332) |
||
| ANC, cells × 109/L | |||||||||||||
| Median Interquartile range (25%–75%) | 3.27 (2.54–4.13) | 2.96 (2.34–3.87) | 2.65 (2.03–3.35) | 2.55 (1.92–3.31) | 5.12 (3.59–7.08) | 1.80 (1.32–2.28) | 1.45 (1.06–1.92) | 1.45 (1.08–1.91) | 1.71 (1.25–2.22) | 1.84 (1.39–2.39) | 1.87 (1.47–2.34) | 1.78 (1.33–2.39) | 1.77 (1.35–2.29) |
| Toxicity grade, ANC, μL | |||||||||||||
| Grade 0: (ANC > 1300) | 466 (98.7) | 417 (98.6) | 339 (93.9) | 249 (93.3) | 439 (97.6) | 336 (76.4) | 244 (59.4) | 257 (62.1) | 285 (72.5) | 280 (80.2) | 293 (84.9) | 244 (76.5) | 259 (78.1) |
| Grade 1: (ANC 1000–1300) | 3 (0.6) | 4 (1.0) | 14 (3.9) | 7 (2.6) | 3 (0.7) | 61 (13.9) | 82 (20.0) | 80 (19.3) | 62 (15.8) | 44 (12.6) | 26 (7.5) | 42 (13.2) | 48 (14.5) |
| Grade 2: (ANC 750–999) | 1 (0.2) | 0 (0) | 7 (1.9) | 7 (2.6) | 1 (0.2) | 27 (6.1) | 51 (12.4) | 51 (12.3) | 31 (7.9) | 16 (4.6) | 19 (5.5) | 20 (6.3) | 21 (6.3) |
| Grade 3: (ANC 500–749) | 2 (0.4) | 2 (0.5) | 0 (0) | 1 (0.4) | 4 (0.9) | 10 (2.3) | 22 (5.4) | 19 (4.6) | 11 (2.8) | 9 (2.6) | 2 (0.6) | 10 (3.1) | 3 (0.9) |
| Grade 4: (ANC < 500) | 0 (0) | 0 (0) | 1 (0.3) | 3 (1.1) | 3 (0.7) | 6 (1.4) | 12 (2.9) | 7 (1.7) | 4 (1.0) | 0 (0) | 5 (1.5) | 3 (0.9) | 1 (0.3) |
Abbreviations: ANC, absolute neutrophil count; WHO, World Health Organization.
Graded according to reference 1.
Women started triple antiretroviral prophylaxis at 34 to 36 weeks’ gestation and continued through postpartum week 24. After postpartum week 24, women who met WHO treatment criteria (CD4 count < 200 cells/mm3 or WHO stage 3 or 4) at enrollment or before 24 weeks’ postpartum remained on triple antiretroviral therapy. An analysis that included an additional 126 ANCs from prepartum and delivery visits from women without a postpartum ANC did not change the median values of prepartum or delivery ANCs in an appreciable manner.